These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 25919172)

  • 1. Gavi's balancing act: Accelerating access to vaccines while ensuring robust national decision-making for sustainable programmes.
    Sosler S; Kallenberg J; Johnson HL
    Vaccine; 2015 May; 33 Suppl 1():A4-5. PubMed ID: 25919172
    [No Abstract]   [Full Text] [Related]  

  • 2. The ProVac initiative and evolving decision support.
    Sanderson CF
    Vaccine; 2015 May; 33 Suppl 1():A8-10. PubMed ID: 25919181
    [No Abstract]   [Full Text] [Related]  

  • 3. Perspectives on the development and use of economic evidence for immunization decision-making in a developing country.
    Molina-Aguilera IB
    Vaccine; 2015 May; 33 Suppl 1():A6-7. PubMed ID: 25919176
    [No Abstract]   [Full Text] [Related]  

  • 4. Foreword.
    Etienne CF
    Vaccine; 2015 May; 33 Suppl 1():A1. PubMed ID: 25919148
    [No Abstract]   [Full Text] [Related]  

  • 5. Perspectives on expanding the evidence base to inform vaccine introduction: Program costing and cost-effectiveness analyses.
    Andrus JK; Walker DG
    Vaccine; 2015 May; 33 Suppl 1():A2-3. PubMed ID: 25919161
    [No Abstract]   [Full Text] [Related]  

  • 6. ProVac Global Initiative: a vision shaped by ten years of supporting evidence-based policy decisions.
    Jauregui B; Janusz CB; Clark AD; Sinha A; Garcia AG; Resch S; Toscano CM; Sanderson C; Andrus JK
    Vaccine; 2015 May; 33 Suppl 1():A21-7. PubMed ID: 25919164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strengthening national decision-making on immunization by building capacity for economic evaluation: Implementing ProVac in Europe.
    Blau J; Hoestlandt C; D Clark A; Baxter L; Felix Garcia AG; Mounaud B; Mosina L
    Vaccine; 2015 May; 33 Suppl 1():A34-9. PubMed ID: 25919171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence-based decision-making for vaccine introductions: Overview of the ProVac International Working Group's experience.
    Jauregui B; Garcia AG; Bess Janusz C; Blau J; Munier A; Atherly D; Mvundura M; Hajjeh R; Lopman B; Clark AD; Baxter L; Hutubessy R; de Quadros C; Andrus JK
    Vaccine; 2015 May; 33 Suppl 1(0 1):A28-33. PubMed ID: 25919170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gavi's Transition Policy: Moving From Development Assistance To Domestic Financing Of Immunization Programs.
    Kallenberg J; Mok W; Newman R; Nguyen A; Ryckman T; Saxenian H; Wilson P
    Health Aff (Millwood); 2016 Feb; 35(2):250-8. PubMed ID: 26858377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What have we learned on costs and financing of routine immunization from the comprehensive multi-year plans in GAVI eligible countries?
    Brenzel L
    Vaccine; 2015 May; 33 Suppl 1():A93-8. PubMed ID: 25919183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Valuing vaccines: deficiencies and remedies.
    Bloom DE
    Vaccine; 2015 Jun; 33 Suppl 2():B29-33. PubMed ID: 26022563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strategies for decision-making on vaccine use: the French experience.
    Loulergue P; Floret D; Launay O
    Expert Rev Vaccines; 2015 Jul; 14(7):917-22. PubMed ID: 25913015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Costs of vaccine programs across 94 low- and middle-income countries.
    Portnoy A; Ozawa S; Grewal S; Norman BA; Rajgopal J; Gorham KM; Haidari LA; Brown ST; Lee BY
    Vaccine; 2015 May; 33 Suppl 1():A99-108. PubMed ID: 25919184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of health economic analyses in vaccine decision making.
    Black S
    Vaccine; 2013 Dec; 31(51):6046-9. PubMed ID: 23968768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strengthening vaccination policies in Latin America: an evidence-based approach.
    Tapia-Conyer R; Betancourt-Cravioto M; Saucedo-Martínez R; Motta-Murguía L; Gallardo-Rincón H
    Vaccine; 2013 Aug; 31(37):3826-33. PubMed ID: 23357196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccination planning in Italy: increasing vaccines while reducing coverage?
    Garattini L; Curto A; Freemantle N
    Expert Rev Pharmacoecon Outcomes Res; 2016 Oct; 16(5):547-548. PubMed ID: 27441592
    [No Abstract]   [Full Text] [Related]  

  • 17. Expanding access to non-traditional vaccines: a perspective from Indonesia.
    Suwantika AA; Postma MJ
    Expert Rev Vaccines; 2014 Dec; 13(12):1419-21. PubMed ID: 25147940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gavi's policy steers country ownership and self-financing of immunization.
    Henderson K; Gouglas D; Craw L
    Vaccine; 2016 Aug; 34(37):4354-9. PubMed ID: 27431423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The decision making process on new vaccines introduction in South Africa.
    Ngcobo NJ; Cameron NA
    Vaccine; 2012 Sep; 30 Suppl 3():C9-13. PubMed ID: 22939028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A systematic review of health economic evaluations of vaccines in Brazil.
    Sartori AMC; Rozman LM; Decimoni TC; Leandro R; Novaes HMD; de Soárez PC
    Hum Vaccin Immunother; 2017 Jun; 13(6):1-12. PubMed ID: 28129026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.